Omeros Corporation (OMER)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.27B
Last updated: Nov 17, 2026 at 11:06 AM ET
Omeros Corporation (OMER) Competitors
The companies most similar to Omeros are Oric Pharmaceuticals (ORIC), Olema Pharmaceuticals (OLMA) and OmniAb (OABI). By market cap, Omeros ranks 7th of the 13 companies on this page; Harmony Biosciences Holdings (HRMY) is the largest at $1.98B.
Peer Comparison
OMER's ROIC of 33.6% is above the peer median of -16.2%, and its revenue growth of 14.9% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Omeros (OMER) | $1.27B | N/A | 16.4x | 324.9% | 33.6% | 14.9% | 0.00% |
| Oric Pharmaceuticals Inc (ORIC) | $814.71M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Olema Pharmaceuticals Inc (OLMA) | $662.30M | N/A | N/A | 0.0% | -53.8% | 0.0% | 0.00% |
| OmniAb Inc. (OABI) | $716.17M | N/A | 15.7x | -108.1% | -17.5% | 78.3% | 0.00% |
| Ocular Therapeutix Inc (OCUL) | $1.37B | N/A | 26.9x | 0.0% | -52.1% | -11.5% | 0.00% |
| Harmony Biosciences Holdings (HRMY) | $1.98B | 9.6x | 1.9x | 18.0% | 13.7% | 12.3% | 0.00% |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | $1.90B | N/A | 168.0x | 0.0% | -104.3% | -100.0% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Corvus Pharmaceuticals Inc (CRVS) | $897.52M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Ultragenyx (RARE) | $1.64B | N/A | 2.2x | -71.8% | N/A | 8.1% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Geron Corporation (GERN) | $622.98M | N/A | 2.9x | -22.0% | -7.4% | 27.4% | 0.00% |
| MannKind Corp (MNKD) | $1.33B | N/A | 3.1x | -18.1% | -10.4% | 24.0% | 0.00% |
| Peer median | $1.11B | 9.6x | 3.1x | 0.0% | -16.2% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Omeros, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Oric Pharmaceuticals Inc (ORIC) | ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. | ORIC competitors |
| Olema Pharmaceuticals Inc (OLMA) | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development... | OLMA competitors |
| OmniAb Inc. (OABI) | OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. | OABI competitors |
| Ocular Therapeutix Inc (OCUL) | Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development... | OCUL competitors |
| Harmony Biosciences Holdings (HRMY) | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. | HRMY competitors |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based... | ZBIO competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| Corvus Pharmaceuticals Inc (CRVS) | Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. | CRVS competitors |
| Ultragenyx (RARE) | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development... | RARE competitors |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Geron Corporation (GERN) | Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic... | GERN competitors |
| MannKind Corp (MNKD) | MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung... | MNKD competitors |
Frequently Asked Questions About OMER
Who are Omeros' main competitors?
The companies most similar to Omeros include Oric Pharmaceuticals (ORIC), Olema Pharmaceuticals (OLMA), OmniAb (OABI), Ocular Therapeutix (OCUL) and Harmony Biosciences Holdings (HRMY), listed from the closest match.
Who is Omeros' biggest competitor?
Harmony Biosciences Holdings (HRMY) is the largest of the similar companies at $1.98B; Oric Pharmaceuticals (ORIC) is the closest match by business profile, size, sector and industry.
How does OMER stock compare with its competitors?
OMER's P/S is 16.4x against a peer median of 3.1x; its net margin is 324.9% against a peer median of 0.0%.
Which of Omeros' competitors pays a higher dividend?
Omeros pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Omeros bigger than its competitors?
No. Omeros is 7th by market cap among the 13 companies on this page; the largest is Harmony Biosciences Holdings (HRMY) at $1.98B.
OMER pages: Overview, Earnings, Forecast, Financials, Competitors